VIMTALABS

Current scenario - Q2 FY27 revenue grew by ~10% YoY, impacted by longer customer decision-making cycles and a temporary lull in the pharma R&D pipeline. - Food testing exports/imports were affected by logistics issues, but domestic opportunities are offsetting this. - Electronics testing remained stable, driven by defense OEMs and strong domestic manufacturing trends. Management Guidance & Outlook - Management remains confident about medium-term growth and reiterates a target of ~20-25% CAGR top-line growth over the medium term. - Expecting improvement in Contract Research and Development Services (CRADS) for large molecules and clinical research in Q3 and Q4. - Planned capex for FY27 is budgeted at approximately INR80 crores. Growth Drivers - Commencement of revenue generation from biologics services, marking a move into commercial delivery. - Preclinical services continue to be a strong growth driver, growing at a ~30% CAGR over the last 4 years. - Expansion of large animal facilities in preclinical and capacity additions in EMI/EMC testing to capture rising domestic demand.

- Vimta Labs Limited has incorporated a Wholly Owned Subsidiary named 'Vimta Labs LLC' in the United States of America (USA) on September 24, 2026. - The subsidiary will operate in the Contract Research Organization sector to support the parent company's core business lines including Preclinical Studies, Clinical Trials, and Analytical testing. - Total cost of investment is USD 8,500 via 100% cash subscription to initial paid-up capital.

- Vimta Labs Limited has informed the exchange regarding the availability of the audio recording for the Q2 FY 2026-27 earnings call held on October 30, 2026. - The audio recording link has been made available on the company website.

Q2 FY27 Total Income ₹1,149 Mn vs ₹1,045 Mn (▲9.9% YoY) EBITDA ₹408 Mn vs ₹369 Mn (▲10.5% YoY) PAT ₹206 Mn vs ₹199 Mn (▲3.5% YoY) EBITDA Margin 35.5% vs 35.3% (▲20bps)

Q2 FY27 Consolidated Revenue from Operations ₹1,120 Mn vs ₹1,018 Mn (▲10.0% YoY) EBITDA ₹408 Mn vs ₹369 Mn (▲10.6% YoY) PAT ₹206 Mn vs ₹199 Mn (▲3.5% YoY) EBITDA Margin 36.4% vs 36.3% (▲10bps)

Q2 FY27 Revenue ₹111.98Cr vs ₹101.85Cr (▲10% YoY) EBITDA ₹37.87Cr vs ₹34.23Cr (▲11% YoY) PAT ₹20.61Cr vs ₹19.92Cr (▲3.5% YoY) EBITDA Margin 33.8% vs 33.6% (▲21bps)

Concall Schedule Concall Date: Friday, 30th October 2026 Concall Time: 02:30 P.M. (IST)

- ESOP Allotment Committee of Vimta Labs Limited allotted 12,955 equity shares of ₹2/- each to eligible employees on September 16, 2026, under the ESOP Plan 2021. - This allotment increased the paid-up share capital from ₹8,93,73,808 to ₹8,93,99,718.

- Investor/Analyst Meet Schedule - Meeting Date: 11th September 2026 - Meeting Time: 02:00 P.M (IST) - Participant: Mr. Ankit Pandey (Fund Manager), Quant Mutual Fund - Mode: Virtual, One-on-One meeting to understand company's business operations. No unpublished price sensitive information will be shared.

- CARE Ratings Limited reaffirmed credit ratings for Vimta Labs' bank facilities to CARE A; Stable / CARE A1. The outlook remains Stable, reflecting healthy profitability and a conservative capital structure.

- Vimta Labs Limited responded to NSE's query dated 31.08.2026 regarding increased trading volume. The company confirmed all necessary disclosures have been made as per SEBI regulations and attributes share price movement purely to market factors.

- Concall Schedule - Meeting 1: September 04, 2026, 11:00 AM (IST) with Mr. Lukas Davies (Oppenheimer Generations Asia) - Physical Meeting. - Meeting 2: September 09, 2026, 04:00 PM (IST) with Mr. Karan Doshi (Abakkus Asset Management) - Virtual Meeting. - No unpublished price sensitive information will be shared.

- Analyst/Institutional Investor Meetings Scheduled: - Meeting with Mr. Lukas Davies (Oppenheimer Generations Asia) on 04th September 2026 at 11:00 A.M (IST) (Physical Meeting). - Meeting with Mr. Karan Doshi (Abakkus Asset Management) on 09th September 2026 at 04:00 P.M (IST) (Virtual Meeting). - No unpublished price sensitive information will be shared in these meetings.

- Vimta Labs Limited detected a cyber security incident affecting a part of its IT infrastructure. - The company initiated containment measures and engaged external cybersecurity experts. - Operations and customer delivery services have remained fully functional with no material impact identified on operations thus far.

- Investor/Analyst Meet Schedule - Meeting Date: 31st July 2026 - Type: Virtual One-on-One meetings with Ms. Pragati Khadse (Nine Rivers Capital) and Mr. Avnish Tiwari & Mr. Avnish Burman (Vaikarya Change). - Agenda: To understand company's business operations.

- Analyst/Institutional Investor Meets Scheduled - Date: July 31, 2026 - Meeting 1: 03:30 P.M - 04:30 P.M (IST) with Ms. Pragati Khadse (Nine Rivers Capital) - Meeting 2: 04:30 P.M - 05:30 P.M (IST) with Mr. Avnish Tiwari & Mr. Avnish Burman (Vaikarya Change) - Agenda: To understand company's business operations.

- Management reiterated an aspiration for 20-25% growth for FY27, despite some Q1 challenges in the food and environment business due to global issues. - Q1 FY27 Total Income grew by 13.7% YoY to INR1,129 million. - EBITDA increased by 16% YoY to INR411 million, and PAT grew by 11.4% YoY to INR210 million. - EBITDA margins for Q1 FY27 stood at 36.4%, showing YoY improvement, and PAT margins at 18.6%. - The company secured its first order for Biologics services and operationalized the facility, with commercialization starting in Q1, expecting significant contribution from the third year onwards. - FY27 Capex budget is approximately INR80 crores, including INR10 crores for Biologics CRADs, aimed at strengthening analytical capabilities and expanding service offerings. - Management expressed confidence in medium- to long-term opportunities, citing positive enquiry trends, healthy demand visibility, and strong performance in pharma services, particularly in the U.S. market.